Trial Profile
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Exploratory Dose-response Study to Assess the Efficacy and Safety of Different Oral Doses of BAY1128688 in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs BAY 1128688 (Primary)
- Indications Endometriosis; Pelvic pain
- Focus Therapeutic Use
- Acronyms AKRENDO1
- Sponsors Bayer
- 09 Jul 2023 Results of a clinical trial (AKRENDO1) the effects of BAY1128688 in adult premenopausal women with endometriosis-related pain symptoms over a 12-week treatment period published in the Drugs in R and D
- 28 Feb 2019 This trial was discontinued in Netherlands, according to European Clinical Trials Database.
- 29 Nov 2018 Status changed from active, no longer recruiting to discontinued.